When making this switch, the dose translation is critical
New Phytol 224:15691584 Maynard D, Kumar V, Spro J, Dietz K-J (2020) 12-Oxophytodienoic acid reductase 3 (OPR3) functions as NADPH-dependent , -ketoalkene reductase in detoxification and monodehydroascorbate reductase in redox homeostasis
In fact, more than 35% of American pharmaceutical advertisement spending in 2025 went into GLP-1 marketing, according to market research company eMarketer
My question: given my MS stability but significant metabolic risk factors (obesity, pre-diabetes, cholesterol, thyroid), do you think a GLP-1 agonist (such as tirzepatide or semaglutide) would be a reasonable option for me
Additionally, Ive personally used Saxenda, Wegovy, and Zepbound and experienced positive results
Others may not realise that over a quarter of a billion rare disease sufferers in this World are currently receiving little or no appropriate treatment for the conditions they suffer from